Study on the Pathogenesis of Retinal Vascular Diseases Based on Body Fluid Metabolomics

May 7, 2024 updated by: Zhongnan Hospital
Through the analysis of metabolites in body fluids (intraocular fluid, plasma) of patients with retinal vascular diseases (retinal vein occlusion, diabetic retinopathy), the possible pathogenesis of retinal vein occlusion was explored.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

1. Clinical data of patients with RVO and DR Were retrospectively studied to analyze their pathogenesis. 2. Metabolomic studies were conducted on body fluids (intraocular fluid and peripheral blood) of patients with RVO and DR And control group to find out the differences and find new targets for the prevention and treatment of RVO and DR.

Study Type

Observational

Enrollment (Estimated)

3900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Zhongnan Hospital of Wuhan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with RVO and DR Who were admitted to Zhongnan Hospital of Wuhan University from January 2018 to August 2023 (about 3600 cases)

Description

Inclusion Criteria:

  • Age ≥18 years old
  • Confirmed diagnosis of retinal vein obstruction and diabetic retinopathy through ophthalmic specialist examination

Exclusion Criteria:

  • Severe systemic diseases
  • Pregnant and lactating patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group
Patients with retinal vein obstruction and diabetic retinopathy
Other: etiology
As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
Control group
Cataract surgery and vitrectomy patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Screening of prognostic markers and model validation
Time Frame: 1/12/2024-30/12/2024
  1. Surface markers and key molecules related to the study of diseases were screened out, and a biomarker model for assessing disease prognosis was established.
  2. Candidate differential molecules were screened through a training cohort, a Cox regression model was constructed, and the prognostic value of the model was verified in the test cohort.
1/12/2024-30/12/2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhongnan Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 7, 2023

Primary Completion (Estimated)

October 30, 2024

Study Completion (Estimated)

December 30, 2024

Study Registration Dates

First Submitted

March 21, 2024

First Submitted That Met QC Criteria

May 7, 2024

First Posted (Actual)

May 10, 2024

Study Record Updates

Last Update Posted (Actual)

May 10, 2024

Last Update Submitted That Met QC Criteria

May 7, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20240202

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolomics; Retinopathy; Etiology

Clinical Trials on etiology

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe